Molecular characterization of novel trispecific ErbB-cMet-IGF1R antibodies and their antigen-binding properties.

ABSTRACT: Therapeutic antibodies are well established drugs in diverse medical indications. Their success invigorates research on multi-specific antibodies in order to enhance drug efficacy by co-targeting of receptors and addressing key questions of emerging resistance mechanisms. Despite challenges in production, multi-specific antibodies are potentially more potent biologics for cancer therapy. However, so far only bispecific antibody formats have entered clinical phase testing. For future design of antibodies allowing even more targeting specificities, an understanding of the antigen-binding properties of such molecules is crucial. To this end, we have generated different IgG-like TriMAbs (trispecific, trivalent and tetravalent antibodies) directed against prominent cell surface antigens often d

SUBMITTER: Castoldi R 

PROVIDER: S-EPMC3449402 | biostudies-literature | 2012 Oct

REPOSITORIES: biostudies-literature